Tirzepatide
Farzam K, Patel P.
Journal missing · study guide PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för tirzepatide. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
36 hitsTirzepatide
Författaruppgift saknas
Journal missing · reviewTirzepatide
Författaruppgift saknas
Journal missing · reviewTirzepatide: A New Generation Therapeutic for Diabetes Type 2.
Al-Horani RA, Chedid M.
Endocr Metab Immune Disord Drug Targets · research-article; review; journal article · DOI 10.2174/1871530322666221004151212Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism.
Lee YC, Chung HH.
Br J Clin Pharmacol · letter · DOI 10.1111/bcp.15630Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
Wong E, Cope R, Dima L, Nguyen T.
Am J Ther · review; journal article · DOI 10.1097/mjt.0000000000001588Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.
le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, Machineni S, Dunn J, Chigutsa FB, Ahmad NN, Bunck MC.
Obesity (Silver Spring) · clinical trial protocol; research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/oby.23612Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide.
Wang J, Berglund MR, Braden T, Embry MC, Johnson MD, Groskreutz SR, Sayyed FB, Tsukanov SV, White TD, Jalan A, Seibert KD, Kopach ME.
ACS Omega · research-article; journal article · DOI 10.1021/acsomega.2c05915The <i>catcher in the gut</i>: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity.
Lempesis IG, Liu J, Dalamaga M.
Metabol Open · review-article; review; journal article · DOI 10.1016/j.metop.2022.100220Tirzepatide: A Systematic Update.
Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G.
Int J Mol Sci · review-article; review; journal article · DOI 10.3390/ijms232314631Tirzepatide-Friend or Foe in Diabetic Cancer Patients?
Samuel SM, Varghese E, Kubatka P, Büsselberg D.
Biomolecules · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.3390/biom12111580Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis.
Tang Y, Zhang L, Zeng Y, Wang X, Zhang M.
Front Pharmacol · systematic review; systematic-review; journal article · DOI 10.3389/fphar.2022.1016639Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
Gallwitz B.
Front Endocrinol (Lausanne) · review-article; review; journal article · DOI 10.3389/fendo.2022.1004044Tirzepatide Once Weekly for the Treatment of Obesity.
Dekker TJA.
N Engl J Med · letter; comment · DOI 10.1056/nejmc2211120Tirzepatide Once Weekly for the Treatment of Obesity.
Hagerich K, Durkee M, Goldstein MG.
N Engl J Med · letter; comment · DOI 10.1056/nejmc2211120Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
Razzaki TS, Weiner A, Shukla AP.
Ther Clin Risk Manag · review-article; review; journal article · DOI 10.2147/tcrm.s328056Tirzepatide: A New Anti-Obesity Medication.
Ghoneim S.
Gastroenterology · comment; journal article · DOI 10.1053/j.gastro.2022.09.013Tirzepatide and kidney function: an intriguing and promising observation.
Solini A.
Lancet Diabetes Endocrinol · comment; journal article · DOI 10.1016/s2213-8587(22)00258-3Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.
Lisco G, De Tullio A, Disoteo O, De Geronimo V, Piazzolla G, De Pergola G, Giagulli VA, Jirillo E, Guastamacchia E, Sabbà C, Triggiani V.
Front Endocrinol (Lausanne) · meta-analysis; systematic review; systematic-review; journal article · DOI 10.3389/fendo.2022.920541Tirzepatide highly effective for weight loss.
Tysoe O.
Nat Rev Endocrinol · comment; journal article · DOI 10.1038/s41574-022-00715-1Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA, D'Alessio DA.
Cardiovasc Diabetol · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1186/s12933-022-01604-7Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide.
Patoulias D, Papadopoulos C, Fragakis N, Doumas M.
Am J Cardiol · letter; meta-analysis · DOI 10.1016/j.amjcard.2022.07.003Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.
Chiu N, Aggarwal R, Bhatt DL.
J Am Heart Assoc · letter · DOI 10.1161/jaha.122.026297A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.
Bucheit J, Ayers J, Pamulapati L, Browning A, Sisson E.
J Cardiovasc Pharmacol · review; journal article · DOI 10.1097/fjc.0000000000001299Tirzepatide to treat obesity: phase III results.
Hindson J.
Nat Rev Gastroenterol Hepatol · clinical trial, phase iii; journal article · DOI 10.1038/s41575-022-00657-zTirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.
Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V.
Molecules · review-article; review; journal article · DOI 10.3390/molecules27134315Tirzepatide (Mounjaro) for type 2 diabetes.
Författaruppgift saknas
Med Lett Drugs Ther · journal articleTirzepatide: First Approval.
Syed YY.
Drugs · review; journal article · DOI 10.1007/s40265-022-01746-8Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
Kaneko S.
touchREV Endocrinol · review-article; review; journal article · DOI 10.17925/ee.2022.18.1.10Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators.
N Engl J Med · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.1056/nejmoa2206038